AZN Oct 2024 82.500 put
| Previous close | 4.6500 |
| Open | 4.6500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 82.50 |
| Expiry date | 2024-10-18 |
| Day's range | 4.6500 - 4.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 67 |
Simply Wall St.Admiral Group And Two Other UK Exchange Stocks Estimated As Undervalued For Investment Consideration
The United Kingdom's financial markets are currently poised at a critical juncture, with the FTSE 100's movements closely tied to the upcoming release of May's inflation data and decisions from the Bank of England. Amid these market conditions, identifying undervalued stocks can offer investors potential opportunities for growth in a fluctuating economic environment.
ZacksAstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
AstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.
BenzingaCovid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca
